Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 229

Showing 1-25 of 229 citing articles:

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
The cardio-renal-metabolic connection: a review of the evidence
Marella Marassi, Gian Paolo Fadini
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 88
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 83
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 73
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sudipta Sen, Paul Potnuru, Nadia Hernandez, et al.
JAMA Surgery (2024) Vol. 159, Iss. 6, pp. 660-660
Closed Access | Times Cited: 72
Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
Sneha Annie Sebastian, Inderbir Padda, Gurpreet Johal
Current Problems in Cardiology (2023) Vol. 49, Iss. 2, pp. 102344-102344
Closed Access | Times Cited: 60
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 50
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 47
Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications
Dongrong Yang, Meng‐Yan Wang, Chenglin Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 37
G Protein-Coupled Receptors: A Century of Research and Discovery
Samuel Liu, Preston J. Anderson, Sudarshan Rajagopal, et al.
Circulation Research (2024) Vol. 135, Iss. 1, pp. 174-197
Closed Access | Times Cited: 37
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 28
Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
Brent Hiramoto, Thomas R. McCarty, Nayna A. Lodhia, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 6, pp. 1126-1140
Closed Access | Times Cited: 26
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 22
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
Anastas Kick, Khadija M'Rabet‐Bensalah, Flavio Acquistapace, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 623-637
Open Access | Times Cited: 19
Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials
Yuming Sun, Yongjia Liu, Yating Dian, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 18
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S59-S85
Closed Access | Times Cited: 18
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
David A. Milder, Tamara Y. Milder, S. Liang, et al.
Anaesthesia (2024) Vol. 79, Iss. 7, pp. 735-747
Open Access | Times Cited: 17
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Brady Park, Ehab Bakbak, Hwee Teoh, et al.
AJP Heart and Circulatory Physiology (2024) Vol. 326, Iss. 5, pp. H1159-H1176
Closed Access | Times Cited: 16
Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality
Dror Dicker, Yael Wolff Sagy, Noga Ramot, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2415392-e2415392
Open Access | Times Cited: 16
Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential
Alexander Fuerlinger, Alina Stockner, Simon Sedej, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
Francisco Westermeier, Enrique Z. Fisman
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102181-102181
Open Access | Times Cited: 25
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, et al.
Clinical Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 15
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Rosa F Drummond, Karl Seif, E. Albert Reece
American Journal of Obstetrics and Gynecology (2024) Vol. 232, Iss. 1, pp. 17-25
Closed Access | Times Cited: 15
Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients
Sahib Singh, Aakash Garg, Udaya S. Tantry, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 3, pp. 102403-102403
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top